Schedule a Consultation

Industries We Serve / Ambulatory Infusion Suites

Ambulatory Infusion AdvisoryThe Right Site of Care. Paid What It's Worth.

Payer contracting, drug margin, revenue integrity and growth strategy for infusion suites, infusion centers and the practices and health systems behind them.

Scroll to explore
  • $65.5BMedicare Part B drug spending, 2024MedPAC, Jul 2026
  • 61%Of that spending billed in physician officesMedPAC, Jul 2026
  • 281%Commercial price of hospital-administered drugs, as a share of ASPRAND Round 5.1, Dec 2024
  • 15Drugs in the first Medicare negotiation cycle to include Part BCMS, Jan 2026

The Site-of-Care Spectrum

Four Places to Infuse. Four Ways to Get Paid.

Payers are moving infusions out of the hospital. Select a site.

281%of ASP: average commercial price for hospital-administered drugs

Medicare

Hospital outpatient system (POS 19/22). Most drugs at ASP + 6%; 340B-acquired drugs at ASP − 28% from 2027.

Commercial

The highest-priced site. Medicare pays 106% of ASP for the same drugs.

Watch

Payer site-of-care policies now require medical-necessity review for listed drugs infused here.

1.12×median price over acquisition cost at independent practices

Medicare

Billed as a physician office (POS 11): drug at ASP + 6% plus fee-schedule administration codes, under physician supervision.

Commercial

Non-340B hospitals received a median 2.44× acquisition cost for the same drugs.

Watch

The 2027 fee schedule conversion factor falls 2.31% to $32.63, pulling administration rates with it.

Per Diempharmacy-based suites typically bill like home infusion

Medicare

No Part B pathway for the infusion service. The drug may be covered under Part D; nursing and supplies are not.

Commercial

Per diem and nursing codes under the pharmacy's own payer contracts.

Watch

Major commercial site-of-care policies name ambulatory infusion suites as accepted lower-cost sites.

$196–$401Medicare home infusion payment per visit day, 2027

Medicare

Home infusion therapy benefit since 2021, paid to accredited suppliers by drug category.

Commercial

Per diem plus nursing visits, negotiated with the home infusion provider.

Watch

First doses, reaction risk and nursing capacity limit what can safely move home.

RAND RR-A1144-2-v2, Round 5.1 (Dec 2024; 2020–2022 claims, hospital settings). Robinson, Whaley & Dhruva, NEJM 2024;390:338-45 (BCBS commercial claims 2020–2021; independent practices, not infusion centers specifically). CMS CY2027 OPPS (CMS-1850-F) and PFS (CMS-1848-F) final rules, 4 Nov 2026; CMS CY2027 home infusion therapy rates. NICA and NHIA billing guidance. UnitedHealthcare commercial site-of-care policy, effective 1 Oct 2026.

Infusion Economics

The Same Drug, Very Different Prices

Commercial insurers pay hospitals far more than independent practices for identical drug units. That gap is your leverage.

Median Commercial Price as a Multiple of Acquisition Cost

340B hospitals 3.08×, non-340B hospitals 2.44×, independent physician practices 1.12× acquisition cost.

Robinson, Whaley & Dhruva, NEJM 2024;390:338-45, 57 physician-administered drugs, BCBS commercial claims 2020–2021. Acquisition cost = ASP (0.65 × ASP for 340B hospitals).

  • +276% to +289%Higher prices at non-340B and 340B hospitals than at independent practices, same drug units.
  • 106% of ASPWhat Traditional Medicare pays for most Part B drugs in either setting.
  • Your OpeningAn infusion center can price well above its cost and still save the payer money.

Price Your Site-of-Care Offer

See how much room you have below the hospital rate.

How We Help

Five Ways to Strengthen an Infusion Business

Woman relaxing in an infusion chair with her phone while a nurse checks another patient's IV behind her

Payer Contracting & Site-of-Care Strategy

Rates that reflect the savings you deliver.

  • Drug rates indexed to current ASP
  • Administration and per diem rates
  • Preferred site-of-care designation
  • Network entry for new suites
Two gowned and masked specialists working inside a sterile laminar-flow hood

Drug Margin & Buy-and-Bill

Know what every drug earns, by payer, after acquisition cost.

  • Margin by drug, payer and NDC
  • ASP lag and price-increase exposure
  • White, brown and clear bagging strategy
  • Biosimilar and formulary economics
Analyst reviewing revenue dashboards across dual monitors in a bright, quiet office

Revenue Integrity & Recovery

The drug line carries the dollars, and the leaks.

  • Drug units and NDC reconciliation
  • Administration code hierarchy
  • Prior authorization denial prevention
  • Underpayment recovery on drug lines
Bright infusion room with tall windows where a nurse adjusts an infusion pump beside two patients resting in recliners

Suite Development & Operations

Open or expand suites where payers, referrals and chair capacity line up.

  • Market and feasibility analysis
  • Ownership and billing model choice
  • Chair capacity and scheduling
  • Payer enrollment before opening day
Home infusion nurse checking an older man's IV access while he sits in his living room

Home & Alternate-Site Strategy

For health systems and practices deciding what moves, where, and on whose contract.

  • Hospital-to-office migration planning
  • 340B and site-of-care trade-offs
  • Home infusion partnerships
  • Specialty pharmacy alignment

Infusion Advisory Studio

Model the Infusion Business

Three working models with illustrative defaults. Everything recalculates in your browser.

Per-Infusion Inputs

More assumptions
Payer cost, hospital—
Payer cost, infusion center—
Annual payer savings—
Rate headroom—

Payer Cost per Infusion ($K)

Drug and administration cost per infusion, hospital vs. infusion center.

Navy: drug · Brass: administration and facility. Rate headroom = the highest infusion center drug rate (% of ASP) that still costs the payer no more than the hospital. The default hospital drug rate is RAND Round 5.1's average (281% of ASP); every other default is illustrative. Excludes patient cost sharing and pharmacy benefit (bagged) channels.

—

Payer Mix

Drugs: ASP, acquisition cost and doses
Medicare margin / dose—
Commercial margin / dose—
Annual drug margin—
Margin lost to white bagging—

Margin per Dose by Drug ($)

Medicare and commercial drug margin per dose for each drug.

ASP Lag: If Acquisition Prices Rise Before ASP Catches Up

Acquisition price riseAnnual drug marginChange
None——

Navy: Medicare · Brass: commercial. Medicare pays ASP + 6% (a qualifying biosimilar: its ASP + 8% of the reference product's ASP); sequestration trims 2% from the 80% Medicare pays, leaving roughly ASP + 4.3%. Medicare ASP updates quarterly on sales two quarters old. White-bagged doses earn no drug margin. Excludes coinsurance bad debt, waste, and administration revenue. Illustrative defaults.

Suite Inputs

Hours and per-visit economics
Visit capacity / yr—
Visits at this utilization—
Operating margin / yr—
Break-even utilization—

Operating Margin by Chair Utilization ($M)

Operating margin at utilization from 40% to 90%.

Capacity = chairs × days × hours ÷ chair time. Operating margin = visits × (revenue + drug margin − variable cost) − fixed cost. Magenta bars are losses. Excludes start-up cost, ramp-up and bad debt. Illustrative defaults.

Your contracts, drug list and claims tell the real story.

Request an Infusion Margin Assessment

Policy Watch · 16 November 2026

The Rules Reshaping Infusion

ASP − 28%

340B Drug Payment

Final 2027 hospital outpatient rate for 340B-acquired drugs in non-exempt departments.

CMS-1850-F
106%

Negotiated Part B Prices

Part B will pay 106% of the negotiated price for selected drugs, including Orencia, Entyvio and Xolair, from 2028.

CMS; SSA §1847A
~25%

GLOBE Model

A mandatory CMS test of an international-benchmark Part B rebate in about a quarter of the country, from 2027.

CMS, Sep 2026
12+

Bagging Limits

States banning payer-mandated white and brown bagging, as of August 2025.

AMA

How Each Site Gets Paid

The billing model decides who can contract, and for what.

Hospital OutpatientOffice-Based CenterPharmacy-Based SuiteHome
Medicare claimHospital outpatient system (POS 19/22)Physician fee schedule (POS 11)No Part B infusion pathwayHome infusion therapy benefit
Medicare drugASP + 6%; 340B at ASP − 28%ASP + 6%Part D, where coveredPump-delivered drugs, plus a per-day service payment
CommercialHighest pricesNegotiated % of ASP plus administrationPer diem plus nursingPer diem plus nursing

Sources: CMS CY2027 OPPS final rule fact sheet (4 Nov 2026); CMS IPAY 2028 selected drugs (27 Jan 2026), with Part B status per CMS HCPCS listings; CMS GLOBE Model (30 Sep 2026); AMA State Advocacy Update (1 Aug 2025); CMS place-of-service code set; NHIA and NICA billing guidance; CMS home infusion therapy benefit. Commercial terms vary by contract.

Our Approach

From Drug List to Stronger Contracts

A 90-day assessment, then a 12- to 18-month contracting and performance cycle. Select a phase.

Weeks 1–4

Contract inventory, payer mix and a drug list priced by NDC and payer.

Weeks 4–8

Rates against ASP, payer site-of-care policies and local hospital pricing.

Weeks 8–12

Site-of-care offer, rate targets and a position on bagging for each payer.

Months 4–10

Payer negotiations, preferred-site designations and network entry.

Months 6–18

Drug-line payment audits, quarterly ASP updates and recovery.

Illustrative 18-month workplan.

Illustrative workplan. Timing and outcomes depend on each organization.

Infusion Revenue Check

Where Is Your Infusion Margin Leaking?

Twelve questions with sample answers filled in. Change them to yours. Scored in your browser; nothing is stored or sent.

Contracting
Drug Margin
Revenue Integrity
Site & Growth
Overall score——

Score by domain.

Your Infusion Revenue Summary

Answer the questions to build your summary.

Schedule an Infusion Consultation

A self-assessment for discussion, not an audit. Scoring: Yes 2, Partly 1, No or not sure 0, equally weighted.

Fulcrum Intelligence

Perspectives on Infusion

Questions, Answered

What Is an Ambulatory Infusion Suite?

An ambulatory infusion suite is a non-hospital setting for infused and injected drugs. The industry separates office-based infusion centers, which bill like a physician office, from pharmacy-based suites, which bill like home infusion. We advise both, and the health systems that run their own.

How Does Medicare Pay for Drugs in an Infusion Center?

Office-based centers bill Medicare as a physician office. Most separately paid drugs are paid at ASP plus 6%, and administration is paid under the physician fee schedule. Medicare has no separate infusion-center provider type.

What Is White Bagging?

White bagging is when a payer's specialty pharmacy ships the drug to the infusion site, so the site administers but does not buy or bill the drug. Brown bagging sends it through the patient; clear bagging uses the provider's own specialty pharmacy.

What Are Payer Site-of-Care Programs?

Site-of-care programs require review before certain drugs are infused in a hospital outpatient department, steering stable patients to offices, infusion suites or home. Approval for the hospital setting is typically time-limited.

How Do Biosimilars Affect Infusion Margin?

Medicare pays qualifying biosimilars their ASP plus 8% of the reference product's ASP, while biosimilar competition pushes reference prices down. Margin depends on each payer's rate and the acquisition cost of each product.

How Will Medicare Drug Price Negotiation Affect Infused Drugs?

The 2028 cycle is the first to include Part B drugs. For selected drugs, Medicare will pay 106% of the negotiated price, which changes the drug margin for those products from 2028.

Get Paid for the Value Your Infusion Site Delivers

Payer contracting, drug margin and site-of-care strategy, from one senior team.